Irras AB is Sweden- based medical device company primarily engaged in develops and commercializes solutions that are designed to transform neurocritical care. Company focus on neurosurgical procedures, where excess cerebrospinal fluid (CSF) or toxic blood byproducts often need to be emergently drained and intracranial pressure (ICP) needs to be closely regulated.

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company

Income Statement and Estimates

More financial data

Delayed Nasdaq Stockholm Other stock markets 07:59:43 2023-11-03 EDT			5-day change	1st Jan Change
0.1604 ^SEK	-1.11%		-.--%	-

25-06-27	IRRAS AB Reports Earnings Results for the Full Year Ended December 31, 2024	CI
24-06-17	IRRAS AB Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Market Cap	182M 18.85M 16.48M 15.24M 13.98M 26.47M 1.82B 26.93M 71.4M 887M 70.8M 69.24M 3.06B	P/E 2023	-0.73x	P/E 2024	-1.89x
Enterprise Value	396M 41.03M 35.86M 33.17M 30.43M 57.6M 3.95B 58.6M 155M 1.93B 154M 151M 6.67B	EV / Sales 2023	5.26x	EV / Sales 2024	6.82x
Free-Float	3.55%	Yield 2023 *	-	Yield 2024	-

25-06-27	IRRAS AB Reports Earnings Results for the Full Year Ended December 31, 2024	CI
24-06-17	IRRAS AB Reports Earnings Results for the Full Year Ended December 31, 2023	CI
23-11-03	Irras has today its last day of trading on Nasdaq Stockholm before delisting	FW
23-10-24	IRRAS AB(OM:IRRAS) dropped from OMX Nordic All-Share Index	CI
23-10-24	IRRAS AB(OM:IRRAS) dropped from OMX Nordic Small Cap Index	CI
23-10-23	Irras Obtains Nasdaq Approval for Delisting in Stockholm	MT
23-10-20	Irras delisted from Nasdaq Stockholm with last trading day on November 3	FW
23-10-20	Sweden's Irras Files for Delisting as Privatization Nears Completion	MT
23-10-19	IR Holding Bidco calls for compulsory acquisition in Irras - applies for delisting	FW
23-10-16	Irras Obtains Extension for SEK20 Million Loan	MT
23-10-15	Irras extends SEK 20 million short-term loan	FW
23-10-02	Bidder controls 87.9 percent of the shares in Irras after completion of takeover bid	FW
23-09-18	Set-off issue only realistic option to avoid insolvency situation - Irra Board	FW

23-06-30	Bid for Irras below historical median premium - but also high risk of more fundraising - Afv(R)	FW
23-06-30	Bid for Irras below historical median premium - but also high risk of more fundraising - Afv	FW
23-05-22	Irra's Q1 sales below expectations - Redeye predicts new share issue and halves fair value	FW
23-05-21	Redeye lowers motivated value for Irras to SEK 0.15 (0.30)	FW
23-02-20	Redeye reiterates motivated value for Irras, but predicts capital raising this year	FW

IRRS ABNPV Stock

Stocks

IRRAS

SE0008321202

Medical Equipment, Supplies & Distribution

Valuation: IRRS ABNPV

Latest news : IRRS ABNPV

Analysts' recommendations: IRRS ABNPV

Press Releases: IRRS ABNPV

Quotes and Performance

Course Extremes

Managers and Directors: IRRS ABNPV

Medical Devices & Implants

Financials

Company Profile

Income Statement and Estimates

23-10-20	IRRAS's application for delisting has been approved and the Board of Directors has resolved not to publish the interim report for the third quarter of 2023	AQ
23-10-19	NOTICE TO ATTEND THE EXTRAORDINARY GENERAL MEETING OF IRRAS AB	AQ
23-10-19	IR Holding Bidco Inc. requests compulsory buy-out and IRRAS applies for delisting	AQ
23-10-16	IRRAS publishes prospectus	AQ
23-10-15	IRRAS has extended maturity date for its SEK 20 million short-term loan	AQ

Manager	Title	Age	Since
Will Martin CEO	Chief Executive Officer	51	2021-06-30
Griffen Stapp DFI	Director of Finance/CFO	40	2021-06-16
Sten Gustafsson IRC	Investor Relations Contact	-	2021-03-08

Director	Title	Age	Since
Kleanthis Xanthopoulos BRD	Director/Board Member	68	2015-05-31
Marios Fotiadis CHM	Chairman	53	2020-08-17
Inger Gunnel Anita Tollstadius BRD	Director/Board Member	71	2017-08-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
IRRS ABNPV	-1.11%	-.--%	-.--%	-8.86%	16.9M
STRYKER CORPORATION	+4.16%	+0.71%	-15.72%	+10.32%	121B
SMITH & NEPHEW PLC	+1.04%	+2.87%	+6.06%	-1.61%	13.07B
GLAUKOS CORPORATION	+0.39%	+1.60%	+59.94%	+101.36%	9.21B
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD.	+3.39%	+12.27%	-43.55%	-69.82%	4.2B
DOUBLE MEDICAL TECHNOLOGY INC.	-1.12%	+10.06%	+14.61%	+52.41%	2.91B
BEIJING BALANCE MEDICAL TECHNOLOGY CO.,LTD.	-0.07%	-2.56%	-15.45%	-27.09%	1.73B
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD.	+0.73%	+4.88%	-4.51%	-19.41%	1.67B
ENOVIS CORPORATION	+7.54%	+8.84%	-10.12%	-57.76%	1.47B
Average	+1.68%	+2.99%	-0.97%	-2.27%	17.29B
Weighted average by Cap.	+3.54%	-1.74%	-9.41%	+11.95%

	2023	2024
Net sales	42.88M 4.45M 3.89M 3.6M 3.3M 6.24M 429M 6.35M 16.84M 209M 16.7M 16.34M 723M	57.98M 6.01M 5.26M 4.86M 4.46M 8.44M 580M 8.59M 22.78M 283M 22.59M 22.09M 977M
Net income	-209M -21.67M -18.94M -17.51M -16.07M -30.42M -2.09B -30.95M -82.05M -1.02B -81.37M -79.58M -3.52B	-95.98M -9.96M -8.7M -8.05M -7.39M -13.98M -959M -14.22M -37.71M -469M -37.39M -36.57M -1.62B
Net Debt	43.85M 4.55M 3.98M 3.68M 3.37M 6.39M 438M 6.5M 17.22M 214M 17.08M 16.71M 739M	214M 22.18M 19.38M 17.93M 16.45M 31.13M 2.14B 31.67M 83.98M 1.04B 83.28M 81.45M 3.6B

3 years	0.16	0.19
5 years	0.11	5.31
10 years	0.11	47